On the one hand, DCs can capture antigens in the TME and migrate to the TDLN to activate naive T cells to initiate an immune response; on the other hand, tumor-derived antigens can also be directly drained to the TDLN and cross-presented by resident DCs, which in turn activate effector CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.